Leishmaniasis is endemic in the Mediterranean region, and the prevalence of latent infection in this area is high. Treatment with tumour necrosis factor (TNF) antagonists represents a major breakthrough in the treatment of several inflammatory diseases, including psoriasis. Reports describing opportunistic leishmaniasis in European patients treated with TNF-α antagonist drugs are rapidly accumulating. We describe a case of cutaneous leishmaniasis in a patient treated with infliximab and corticosteroids.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365548.2012.752859 | DOI Listing |
Publication Analysis
Top Keywords
cutaneous leishmaniasis
8
leishmaniasis patient
8
patient receiving
4
receiving infliximab
4
infliximab leishmaniasis
4
leishmaniasis endemic
4
endemic mediterranean
4
mediterranean region
4
region prevalence
4
prevalence latent
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!